Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5734 - Phase II study of NAB-paclitaxel in SensiTivE and Refractory relapsed SCLC (NABSTER TRIAL)


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Francesco Gelsomino


Annals of Oncology (2018) 29 (suppl_8): viii596-viii602. 10.1093/annonc/mdy298


F. Gelsomino1, M. Tiseo2, F. Barbieri3, F. Riccardi4, L. Cavanna5, A. Frassoldati6, A. Delmonte7, L. Longo8, C. Dazzi9, S. Cinieri10, I. Colantonio11, M. Tognetto12, D. Baldari13, L. Tofani13, A. Ardizzoni14

Author affiliations

  • 1 Medical Oncology, AOU Policlinico S. Orsola-Malpighi, 40138 - Bologna/IT
  • 2 Medical Oncology, AOU di Parma, 43126 - Parma/IT
  • 3 Medical Oncology, Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena/IT
  • 4 Medical Oncology, Azienda Ospedaliera Cardarelli, Napoli/IT
  • 5 Oncology Department, Azienda Ospedaliera Piacenza, 29121 - Piacenza/IT
  • 6 Medical Oncology, Azienda Ospedaliera di Ferrara St. Anna, Ferrara/IT
  • 7 N/a, Scientific Institute of Romagna for the Study and Treatment of Cancer, Meldola/IT
  • 8 Medical Oncology, AUSL of Modena, Carpi/IT
  • 9 Medical Oncology, AUSL of Romagna, Ravenna/IT
  • 10 Medical Oncology, Perrino Hospital, Brindisi/IT
  • 11 Medical Oncology, Hospital of Cuneo, Cuneo/IT
  • 12 Medical Oncology, Policlinico S.Orsola-Malpighi, Bologna/IT
  • 13 Clinical Trial Center, Istituto Toscano Tumori, Firenze/IT
  • 14 Division Of Oncology, S.Orsola-Malpighi Hospital, 40138 - Bologna/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5734


Despite high sensitivity to first-line chemotherapy (CT), most small-cell lung cancer (SCLC) patients relapse. Efficacy of 2nd-line CT is modest and influenced by treatment-free-interval (TFI). Topotecan demonstrated modest activity and significant haematological toxicity. Paclitaxel-based regimens showed to be active in this setting. Nab-paclitaxel, compared to paclitaxel, has a reduced incidence of hypersensitivity reactions and of neutropenia. Safety and efficacy in relapsed SCLC have not been prospectively studied.


This open-label phase II study enrolled patients with extensive- (ED) or limited-disease (LD) SCLC progressed during or after etoposide/platinum-based 1st-line CT with the aim to assess the activity and safety of Nab-paclitaxel. Patients were classified as refractory (TFI < 60 days) or sensitive (TFI ≥ 60 days). Eligible patients received Nab-paclitaxel 100 mg/mq on days 1,8,15 every 28 days for 6 cycles, progressive disease or intolerable toxicity. Computed tomography scan was performed every 2 cycles. Treatment could be continued beyond the 6th cycle in presence of prolonged response, clinical benefit and good tolerance to drug. The primary endpoint was objective response, evaluated according to RECIST v1.1 criteria. The secondary endpoints were toxicity, measured according to NCI-CTCAE v4.03, progression-free and overall survival.


From January 2017 to March 2018, 68 patients (25 refractory and 43 sensitive) were enrolled in the modified intentiontotreat population. Median age was 68.5 years (range 44-80). 44 patients were males and 57 had ED. Median follow-up was 5.8 months (IQR 3.37.1). Objective responses are currently being reviewed by an independent radiology panel. Most common toxicities (of all grades) were anemia (39%), leukopenia (27%), neutropenia (28%), nausea (19%), diarrhoea (21%), fatigue (52%), peripheral neuropathy (19%). The only severe toxicity (grade ≥3) was neutropenia (9%). In 13 patients treatment is still ongoing while 3/55 (5%) patients discontinued treatment for toxicity.


This is the first prospective study of Nab-paclitaxel for relapsed SCLC. Nab-paclitaxel demonstrated a manageable toxicity profile. Final activity data will be available for the meeting.

Clinical trial identification

EudraCT: 2016-000408-27; NCT03219762.

Legal entity responsible for the study

GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica).



Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.